Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Guardion Health Sciences Inc is a drug manufacturers-specialty & generic business based in the US. Guardion Health Sciences shares (GHSI) are listed on the NASDAQ and all prices are listed in US Dollars. Guardion Health Sciences employs 12 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.50|
|52-week range||$0.96 - $8.40|
|50-day moving average||$1.16|
|200-day moving average||$1.46|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.68|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||41.51%|
|1 month (2021-09-28)||18.11%|
|3 months (2021-07-28)||6.38%|
|6 months (2021-04-28)||-17.58%|
|1 year (2020-10-27)||38.12%|
|2 years (2019-10-25)||-42.40%|
|3 years (2018-10-24)||N/A|
|5 years (2016-10-24)||N/A|
|Revenue TTM||$1.9 million|
|Gross profit TTM||$-56,791|
|Return on assets TTM||-23.94%|
|Return on equity TTM||-48.96%|
|Market capitalisation||$24.7 million|
TTM: trailing 12 months
There are currently 452,186 Guardion Health Sciences shares held short by investors – that's known as Guardion Health Sciences's "short interest". This figure is 152% up from 179,426 last month.
There are a few different ways that this level of interest in shorting Guardion Health Sciences shares can be evaluated.
Guardion Health Sciences's "short interest ratio" (SIR) is the quantity of Guardion Health Sciences shares currently shorted divided by the average quantity of Guardion Health Sciences shares traded daily (recently around 233085.56701031). Guardion Health Sciences's SIR currently stands at 1.94. In other words for every 100,000 Guardion Health Sciences shares traded daily on the market, roughly 1940 shares are currently held short.
However Guardion Health Sciences's short interest can also be evaluated against the total number of Guardion Health Sciences shares, or, against the total number of tradable Guardion Health Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Guardion Health Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Guardion Health Sciences shares in existence, roughly 20 shares are currently held short) or 0.019% of the tradable shares (for every 100,000 tradable Guardion Health Sciences shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Guardion Health Sciences.
Find out more about how you can short Guardion Health Sciences stock.
We're not expecting Guardion Health Sciences to pay a dividend over the next 12 months.
Guardion Health Sciences's shares were split on a 1:6 basis on 28 February 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Guardion Health Sciences shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Guardion Health Sciences shares which in turn could have impacted Guardion Health Sciences's share price.
Over the last 12 months, Guardion Health Sciences's shares have ranged in value from as little as $0.96 up to $8.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardion Health Sciences's is 0.0623. This would suggest that Guardion Health Sciences's shares are less volatile than average (for this exchange).
Guardion Health Sciences, Inc. , together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It also provides MapcatSF, a medical device that measures the macular pigment optical density; CSV-1000 device that offers auto-calibrated tests to ensure the correct testing luminance and contrast levels; and CSV-2000, a digital standardized contrast sensitivity testing device, as well as develops, manufactures, and sells equipment and supplies for standardized vision testing under the VectorVision name for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. In addition, the company develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.